Palivizumab

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections.[4][3] It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.[4][3] The most common side effects include fever and rash.[4]&a... [wikipedia]